Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

NCT04959032 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Lumateperone 42 mg
DRUG: Placebo

Sponsor

Intra-Cellular Therapies, Inc.